Immunotherapy has transformed cancer treatment, but persistent challenges, such as T cell exhaustion, limited persistence, ...

Tumors are often infiltrated by T lymphocytes recognizing either self- or mutated antigens but are generally inactive, although they often show signs of prior clonal expansion. Hypothesizing that this ...

Genetic polymorphisms of metabolizing enzymes and transporters correlate with pharmacokinetics (PK) and pharmacodynamics (PD) of amrubicin. Background: CTL-associated antigen 4 (CTLA4) is a ...

The first tool is an endogenous RNA, or RNA originating from the body's own cells, called RN7SL1. However, when delivered to a tumor by CAR T cells, RN7SL1 mimics a viral RNA. Just like after a virus ...

(1) A chimeric antigen receptor (CAR) is a modular, synthetic receptor that endows T cells with different targeting abilities. Several emerging engineering approaches aim to improve the safety, ...

First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I.

An antigen is any substance that can trigger an immune response in the body. Antigens are typically proteins or polysaccharides that are recognized as foreign or potentially harmful by the immune ...

Chimeric antigen receptor (CAR) T cell therapy, which uses engineered T cells to treat certain types of cancers, has often been a challenging approach to treating solid tumors. CAR T cells need to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The monoclonal antibody bamlanivimab may ...

With $1.6 million from CPRIT, investigators are testing an endogenous T-cell therapy that has certain advantages over CAR ...